breast cancer uk limited
breast cancer uk limited Company Information
Company Number
07348408
Next Accounts
18 days late
Industry
Other human health activities
Shareholders
-
Group Structure
View All
Contact
Registered Address
c/o goldwins 75 maygrove road, london, NW6 2EG
Website
http://breastcanceruk.org.ukbreast cancer uk limited Estimated Valuation
Pomanda estimates the enterprise value of BREAST CANCER UK LIMITED at £910.3k based on a Turnover of £1.6m and 0.57x industry multiple (adjusted for size and gross margin).
breast cancer uk limited Estimated Valuation
Pomanda estimates the enterprise value of BREAST CANCER UK LIMITED at £4.4m based on an EBITDA of £1m and a 4.37x industry multiple (adjusted for size and gross margin).
breast cancer uk limited Estimated Valuation
Pomanda estimates the enterprise value of BREAST CANCER UK LIMITED at £4.4m based on Net Assets of £1.8m and 2.49x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Breast Cancer Uk Limited Overview
Breast Cancer Uk Limited is a live company located in london, NW6 2EG with a Companies House number of 07348408. It operates in the other human health activities sector, SIC Code 86900. Founded in August 2010, it's largest shareholder is unknown. Breast Cancer Uk Limited is a established, small sized company, Pomanda has estimated its turnover at £1.6m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Breast Cancer Uk Limited Health Check
Pomanda's financial health check has awarded Breast Cancer Uk Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 7 measures and has 3 areas for improvement. Company Health Check FAQs
7 Strong
1 Regular
3 Weak
Size
annual sales of £1.6m, make it larger than the average company (£712.3k)
£1.6m - Breast Cancer Uk Limited
£712.3k - Industry AVG
Growth
3 year (CAGR) sales growth of 58%, show it is growing at a faster rate (5.4%)
58% - Breast Cancer Uk Limited
5.4% - Industry AVG
Production
with a gross margin of 37.4%, this company has a comparable cost of product (37.4%)
37.4% - Breast Cancer Uk Limited
37.4% - Industry AVG
Profitability
an operating margin of 63.9% make it more profitable than the average company (6%)
63.9% - Breast Cancer Uk Limited
6% - Industry AVG
Employees
with 14 employees, this is below the industry average (19)
14 - Breast Cancer Uk Limited
19 - Industry AVG
Pay Structure
on an average salary of £33k, the company has a higher pay structure (£25k)
£33k - Breast Cancer Uk Limited
£25k - Industry AVG
Efficiency
resulting in sales per employee of £113.3k, this is more efficient (£44.4k)
£113.3k - Breast Cancer Uk Limited
£44.4k - Industry AVG
Debtor Days
it gets paid by customers after 5 days, this is earlier than average (23 days)
5 days - Breast Cancer Uk Limited
23 days - Industry AVG
Creditor Days
its suppliers are paid after 5 days, this is quicker than average (19 days)
5 days - Breast Cancer Uk Limited
19 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Breast Cancer Uk Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 920 weeks, this is more cash available to meet short term requirements (135 weeks)
920 weeks - Breast Cancer Uk Limited
135 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 11%, this is a lower level of debt than the average (22.9%)
11% - Breast Cancer Uk Limited
22.9% - Industry AVG
BREAST CANCER UK LIMITED financials
Breast Cancer Uk Limited's latest turnover from March 2023 is £1.6 million and the company has net assets of £1.8 million. According to their latest financial statements, Breast Cancer Uk Limited has 14 employees and maintains cash reserves of £1.9 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 1,585,839 | 929,874 | 712,994 | 401,896 | 399,155 | 433,390 | 319,965 | 289,636 | 296,961 | 107,060 | 93,837 | 217,966 | |
| Other Income Or Grants | |||||||||||||
| Cost Of Sales | |||||||||||||
| Gross Profit | |||||||||||||
| Admin Expenses | |||||||||||||
| Operating Profit | |||||||||||||
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Pre-Tax Profit | 874,109 | 227,323 | 311,467 | -72,109 | 13,969 | -24,842 | 25,446 | 21,585 | 167,538 | -31,381 | 3,369 | 162,343 | |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Profit After Tax | 874,109 | 227,323 | 311,467 | -72,109 | 13,969 | -24,842 | 25,446 | 21,585 | 167,538 | -31,381 | 3,369 | 162,343 | |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Retained Profit | 874,109 | 227,323 | 311,467 | -72,109 | 13,969 | -24,842 | 25,446 | 21,585 | 167,538 | -31,381 | 3,369 | 162,343 | |
| Employee Costs | 462,695 | 315,344 | 294,516 | 309,739 | 44,079 | 76,685 | 19,996 | 122,431 | 73,968 | 69,318 | 55,418 | ||
| Number Of Employees | 14 | 10 | 10 | 10 | 9 | 9 | 6 | 5 | |||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 1,233 | 2,473 | 1,963 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 1,233 | 2,473 | 1,963 | 0 | 0 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 24,889 | 11,184 | 27,266 | 6,730 | 0 | 0 | 0 | 0 | 0 | 0 | 1,051 | 404 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 13,857 | 2,188 | 1,527 | 1,147 | 9,086 | 2,894 | 0 | 2,535 | 250 | 0 | 0 | 0 | 0 |
| Cash | 1,932,025 | 1,147,590 | 725,549 | 442,163 | 533,195 | 545,892 | 461,475 | 437,623 | 374,723 | 213,978 | 250,876 | 236,913 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 1,970,771 | 1,160,962 | 754,342 | 450,040 | 542,281 | 548,786 | 461,475 | 440,158 | 374,973 | 213,978 | 251,927 | 237,317 | 0 |
| total assets | 1,970,771 | 1,160,962 | 754,342 | 450,040 | 542,281 | 548,786 | 462,708 | 442,631 | 376,936 | 213,978 | 251,927 | 237,317 | 0 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 15,414 | 4,191 | 21,982 | 1,346 | 2,085 | 1,652 | 1,401 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 93,696 | 136,128 | 71,887 | 58,822 | 81,253 | 79,660 | 37,991 | 44,761 | 650 | 5,230 | 11,798 | 557 | 0 |
| total current liabilities | 109,110 | 140,319 | 93,869 | 60,168 | 83,338 | 81,312 | 39,392 | 44,761 | 650 | 5,230 | 11,798 | 557 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 108,428 | 141,519 | 8,672 | 49,538 | 46,500 | 69,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 108,428 | 141,519 | 8,672 | 49,538 | 46,500 | 69,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 217,538 | 281,838 | 102,541 | 109,706 | 129,838 | 150,312 | 39,392 | 44,761 | 650 | 5,230 | 11,798 | 557 | 0 |
| net assets | 1,753,233 | 879,124 | 651,801 | 340,334 | 412,443 | 398,474 | 423,316 | 397,870 | 376,286 | 208,748 | 240,129 | 236,760 | 0 |
| total shareholders funds | 1,753,233 | 879,124 | 651,801 | 340,334 | 412,443 | 398,474 | 423,316 | 397,870 | 376,286 | 208,748 | 240,129 | 236,760 | 0 |
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||
| Operating Profit | |||||||||||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1,233 | 1,240 | 1,133 | 115 | 0 | 0 | 0 | |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 25,374 | -15,421 | 20,916 | -1,209 | 6,192 | 2,894 | -2,535 | 2,285 | 250 | -1,051 | 647 | 404 | 0 |
| Creditors | 11,223 | -17,791 | 20,636 | -739 | 433 | 251 | 1,401 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | -75,523 | 197,088 | -27,801 | -19,393 | -20,907 | 110,669 | -6,770 | 44,111 | -4,580 | -6,568 | 11,241 | 557 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | |||||||||||||
| Investing Activities | |||||||||||||
| capital expenditure | 0 | 0 | 0 | ||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | 0 | 0 | 0 | ||||||||||
| Financing Activities | |||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||||
| interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| cash flow from financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 74,417 | |
| cash and cash equivalents | |||||||||||||
| cash | 784,435 | 422,041 | 283,386 | -91,032 | -12,697 | 84,417 | 23,852 | 62,900 | 160,745 | -36,898 | 13,963 | 236,913 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 784,435 | 422,041 | 283,386 | -91,032 | -12,697 | 84,417 | 23,852 | 62,900 | 160,745 | -36,898 | 13,963 | 236,913 | 0 |
breast cancer uk limited Credit Report and Business Information
Breast Cancer Uk Limited Competitor Analysis
Perform a competitor analysis for breast cancer uk limited by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other small companies, companies in NW6 area or any other competitors across 12 key performance metrics.
breast cancer uk limited Ownership
BREAST CANCER UK LIMITED group structure
Breast Cancer Uk Limited has no subsidiary companies.
Ultimate parent company
BREAST CANCER UK LIMITED
07348408
breast cancer uk limited directors
Breast Cancer Uk Limited currently has 8 directors. The longest serving directors include Mrs Ruth Freeborough (Jul 2017) and Mr Mark Jarvis (Apr 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mrs Ruth Freeborough | England | 61 years | Jul 2017 | - | Director |
| Mr Mark Jarvis | England | 63 years | Apr 2020 | - | Director |
| Miss Margot Black | England | 34 years | Apr 2020 | - | Director |
| Ms Clelia Froguel | England | 38 years | Jun 2022 | - | Director |
| Mrs Lotte Spencer | England | 49 years | Mar 2024 | - | Director |
| Ms Nazia Tingay | England | 53 years | Mar 2024 | - | Director |
| Dr Silvy Mardiguian | England | 42 years | Mar 2024 | - | Director |
| Mrs Beezy Marsh | England | 56 years | Mar 2024 | - | Director |
P&L
March 2023turnover
1.6m
+71%
operating profit
1m
0%
gross margin
37.5%
+3.04%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
1.8m
+0.99%
total assets
2m
+0.7%
cash
1.9m
+0.68%
net assets
Total assets minus all liabilities
Similar Companies
breast cancer uk limited company details
company number
07348408
Type
Private Ltd By Guarantee w/o Share Cap
industry
86900 - Other human health activities
incorporation date
August 2010
age
15
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
March 2023
previous names
N/A
accountant
-
auditor
ASTON SHAW LIMITED
address
c/o goldwins 75 maygrove road, london, NW6 2EG
Bank
CO-OPERATIVE BANK PLC
Legal Advisor
-
breast cancer uk limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to breast cancer uk limited.
breast cancer uk limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for BREAST CANCER UK LIMITED. This can take several minutes, an email will notify you when this has completed.
breast cancer uk limited Companies House Filings - See Documents
| date | description | view/download |
|---|
